An Updated Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) Versus Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Kim Linton, et al.

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
JournalTransplantation and Cellular Therapy
Volume30
Issue number2 S1
DOIs
Publication statusPublished - 7 Feb 2024
EventTransplantation & Cellular Therapy Meetings of ASTCT and CIBMTR: ASTCT CIBMTR 2024 - San Antonio, United States
Duration: 21 Feb 202424 Feb 2024
https://tandem.confex.com/tandem/2024/meetingapp.cgi/

Cite this